Eli Lilly and Co. (LLY) said that it has reached a multi-year research collaboration and licensing agreement with Regor Therapeutics Group to discover, develop and commercialize novel therapies for metabolic disorders.
As per the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license.
Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan, where Regor will maintain these rights and responsibilities.
Regor will receive an upfront payment of up to $50 million, which partially includes an equity investment by Lilly in Regor. The company is also eligible to receive up to $1.5 billion in potential payments based on the achievement of prespecified preclinical, clinical development and commercial milestones, as well as tiered royalties from low-single to low-double digits on sales resulting from the agreement.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.